{
    "paper_id": "PMC7118687",
    "metadata": {
        "title": "Options th\u00e9rapeutiques de prise en charge des sarcomes durant la pand\u00e9mie COVID-19\u00a0: propositions du groupe sarcome fran\u00e7ais",
        "authors": [
            {
                "first": "Nicolas",
                "middle": [],
                "last": "Penel",
                "suffix": "",
                "email": "n-penel@o-lambret.fr",
                "affiliation": {}
            },
            {
                "first": "Sylvie",
                "middle": [],
                "last": "Bonvalot",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "V\u00e9ronique",
                "middle": [],
                "last": "Minard",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Daniel",
                "middle": [],
                "last": "Orbach",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Fran\u00e7ois",
                "middle": [],
                "last": "Gouin",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Nad\u00e8ge",
                "middle": [],
                "last": "Corradini",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Mehdi",
                "middle": [],
                "last": "Brahmi",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Perrine",
                "middle": [],
                "last": "Marec-Berard",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Sylvain",
                "middle": [],
                "last": "Briand",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Nathalie",
                "middle": [],
                "last": "Gaspar",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Carmen",
                "middle": [],
                "last": "Llacer",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "S\u00e9bastien",
                "middle": [],
                "last": "Carrere",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Armelle",
                "middle": [],
                "last": "Dufresne",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Axel",
                "middle": [],
                "last": "Le Cesne",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Jean-Yves",
                "middle": [],
                "last": "Blay",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Nous proposons compte-tenu de l\u2019urgence sanitaire une adaptation des recommandations th\u00e9rapeutiques.",
            "cite_spans": [],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "La pr\u00e9sence du virus doit \u00eatre recherch\u00e9e chez les patients avec suspicion d\u2019infection COVID-19 (crit\u00e8res cliniques et/ou scanographiques). L e traitement doit alors \u00eatre d\u00e9cal\u00e9 de 15 jours \u00e0 partir du d\u00e9but des sympt\u00f4mes, si le patient est asymptomatique.",
            "cite_spans": [],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "Les r\u00e9unions de concertation pluridisciplinaire labellis\u00e9es restent \u00e0 la disposition de chacun. Il est pr\u00e9f\u00e9rable d\u2019\u00e9changer par t\u00e9l\u00e9conf\u00e9rence ou visioconf\u00e9rence. N\u2019h\u00e9sitez pas \u00e0 contacter le responsable de la RCP Sarcome locale : https://expertisesarcome.org/centres-experts-par-region/.",
            "cite_spans": [],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "Pour les formes localis\u00e9es :\u2022les recommandations de pratiques cliniques ESMO [1], [2], [3] s\u2019appliquent sans modification pour les patients sans sympt\u00f4mes d\u2019infection par COVID-19 ;\u2022ne pas repousser la chirurgie pour les patients op\u00e9rables, sans sympt\u00f4mes COVID : sarcomes des tissus mous de grade 2\u20133, sarcomes osseux, tumeurs gastro-intestinales digestives (GIST) et sarcomes visc\u00e9raux ;\u2022en cas de chirurgie lourde (type sarcome r\u00e9trop\u00e9riton\u00e9al) : s\u2019assurer des capacit\u00e9s de r\u00e9animation postop\u00e9ratoire ;\u2022la radioth\u00e9rapie adjuvante des sarcomes des tissus mous ne doit pas \u00eatre retard\u00e9e ;\u2022pour les sarcomes des tissus mous, la chimioth\u00e9rapie n\u00e9o-adjuvante est \u00e0 r\u00e9server aux patients inop\u00e9rables ou chez qui la seule intervention possible est mutilante. Discuter aussi la radioth\u00e9rapie pr\u00e9op\u00e9ratoire, selon la localisation et le type histologique ;\u2022sarcomes d\u2019Ewing et ost\u00e9osarcomes : maintenir les programmes de chimioth\u00e9rapies n\u00e9o-adjuvantes et adjuvantes, sans modification pour les patients sans sympt\u00f4mes d\u2019infection par COVID-19 ;\u2022rhabdomyosarcomes alv\u00e9olaires et embryonnaires : maintenir les programmes de chimioth\u00e9rapies n\u00e9o-adjuvantes et adjuvantes, sans modification pour les patients sans sympt\u00f4mes d\u2019infection par COVID-19 ;\u2022fibromatoses desmo\u00efdes et tumeurs conjonctives \u00e0 malignit\u00e9 interm\u00e9diaire : privil\u00e9gier la surveillance active ; en cas de maladie \u00e9volutive : privil\u00e9gier une option sans AINS [4] ;\u2022pour les GIST \u00e0 haut risque de rechute, initier le traitement adjuvant par imatinib.\n",
            "cite_spans": [
                {
                    "start": 77,
                    "end": 80,
                    "mention": "[1]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 82,
                    "end": 85,
                    "mention": "[2]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 87,
                    "end": 90,
                    "mention": "[3]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1414,
                    "end": 1417,
                    "mention": "[4]",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "Pour les formes m\u00e9tastatiques:\u2022sarcomes des tissus mous : en phase m\u00e9tastatique, le traitement de premi\u00e8re ligne reste une chimioth\u00e9rapie avec doxorubicine, avec facteurs de croissances syst\u00e9matiques : \u2218mais proposition de polychimioth\u00e9rapie par doxorubicine et dacarbazine si l\u00e9iomyosarcome avec m\u00e9tastases pulmonaires limit\u00e9es sans extension extra-thoracique et accessibles \u00e0 une chirurgie thoracique,\u2218et proposition de polychimioth\u00e9rapie par doxorubicine et ifosfamide pour les autres histologies avec m\u00e9tastases pulmonaires limit\u00e9es sans extension extra-thoracique et accessibles \u00e0 une chirurgie thoracique) ;\n\u2022sarcomes des tissus mous : les traitements des deuxi\u00e8me ligne et au-del\u00e0 peuvent \u00eatre prescrits selon les recommandations de pratique habituelle : les traitements par voie orale (pazopanib, voire regorafenib) peuvent \u00eatre privil\u00e9gi\u00e9s pour limiter les d\u00e9placement des patients pour les sarcomes non liposarcome. Pour les liposarcomes : trabectedin ou eribuline ;\u2022GIST : les recommandations s\u2019appliquent avec imatinib et en phase m\u00e9tastatique (pour sunitinib et r\u00e9gorafenib) ;\u2022sarcomes osseux d\u2019embl\u00e9e m\u00e9tastatiques : ost\u00e9osarcomes et sarcomes d\u2019Ewing d\u2019embl\u00e9e m\u00e9tastatique (traitement de premi\u00e8re ligne classique, par exemple VDC-IE pour les sarcomes Ewing) ;\u2022rechute m\u00e9tastatique des sarcomes osseux : topotecan et cyclophosphamide pour les sarcomes d\u2019Ewing ; pas de standard th\u00e9rapeutique pour les ost\u00e9osarcomes : discuter un traitement anti-angiog\u00e9nique.\n",
            "cite_spans": [],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "Regarding the COVID-19 outbreak, we propose an adaptation of current recommendations for clinical practice.",
            "cite_spans": [],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "Patients with suspected COVID-19 should be screened for the presence of the virus. If confirmed or highly suspected (clinically or CT-scan), any treatment must be postponed at least 15 days after the start of the symptoms and when the patient has recovered.",
            "cite_spans": [],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "Multidisciplinary tumor boards remain at your disposition for virtual discussion. Contact the manager of your local MDT.",
            "cite_spans": [],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "Localized sarcoma:\u2022ESMO [1], [2], [3] Clinical Practice Recommendations apply without modification for patients without of COVID-19 symptoms;\u2022do not delay surgery for operable patients without COVID-19 symptoms: grade 2\u20133 soft tissue sarcoma, bone sarcoma, GIST and visceral sarcoma;\u2022in the case of high-risk surgery (retroperitoneal sarcoma): ensure postoperative resuscitation capacities;\u2022radiation therapy for soft tissue sarcoma should not be delayed;\u2022for soft tissue sarcoma, neo-adjuvant chemotherapy should be reserved for patients who are inoperable or in whom the only possible intervention is mutilating. Also discuss preoperative radiotherapy, depending on location and histological type;\u2022Ewing and Osteosarcoma Sarcomas: Maintain neo-adjuvant and adjuvant chemotherapy regimens, without modification for patients without symptoms of COVID-19 infection;\u2022alveolar and embryonic rhabdomyosarcoma: maintain neo-adjuvant and adjuvant chemotherapy programs, without modification for patients without symptoms of COVID-19 infection;\u2022connective tumors with intermediate malignancy: favor active surveillance; in the event of progressive disease: favor an option without NSAIDs [4];\u2022for GIST at high risk of relapse, initiate adjuvant treatment with imatinib.\n",
            "cite_spans": [
                {
                    "start": 24,
                    "end": 27,
                    "mention": "[1]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 29,
                    "end": 32,
                    "mention": "[2]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 34,
                    "end": 37,
                    "mention": "[3]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1181,
                    "end": 1184,
                    "mention": "[4]",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "Advanced disease:\u2022soft tissue sarcoma: in the metastatic phase, first-line treatment remains chemotherapy with doxorubicin, with systematic growth factors:\u2218doxorubicin-dacarabazine if leiomyosarcoma with limited pulmonary metastases without extra-thoracic extension and accessible to chest surgery,\u2218doxorubicin-ifosfamide for other histologies with limited lung metastases without extra-thoracic extension and accessible to chest surgery;\n\u2022soft tissue sarcomas: second-lien treatment and beyond may be prescribed according to practice recommendations: oral treatments (pazopanib, or even regorafenib) may be preferred to limit the movement of patients for non-liposarcoma sarcoma. For liposarcomes: trabectedin or eribulin;\u2022GIST: the recommendations apply with imatinib and in the metastatic phase (then sunitinib and regorafenib);\u2022bone sarcomas with metastasis at diagnosis: classical first-line treatment, e.g. VDC-IE for Ewing sarcoma;\u2022metastatic relapse of bone sarcoma: topotecan and cyclophosphamide for Ewing's sarcoma; no standard of care for osteosarcomas (discuss anti-angiogenic treatment, e.g. regorafenib or pazopanib).\n",
            "cite_spans": [],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "aucun.",
            "cite_spans": [],
            "section": "Financement",
            "ref_spans": []
        },
        {
            "text": "les auteurs d\u00e9clarent ne pas avoir de liens d\u2019int\u00e9r\u00eats.",
            "cite_spans": [],
            "section": "D\u00e9claration de liens d\u2019int\u00e9r\u00eats",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)",
            "authors": [
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Kasper",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Baumgarten",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Garcia",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Bonvalot",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Haas",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Ann Oncol",
            "volume": "28",
            "issn": "",
            "pages": "2399-2408",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up",
            "authors": [
                {
                    "first": "P.G.",
                    "middle": [],
                    "last": "Casali",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Bielack",
                    "suffix": ""
                },
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Abecassis",
                    "suffix": ""
                },
                {
                    "first": "H.T.",
                    "middle": [],
                    "last": "Aro",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Bauer",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Ann Oncol",
            "volume": "29",
            "issn": "Suppl 4",
            "pages": "iv79-iv95",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up",
            "authors": [
                {
                    "first": "P.G.",
                    "middle": [],
                    "last": "Casali",
                    "suffix": ""
                },
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Abecassis",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Bauer",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Biagini",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Bielack",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Ann Oncol",
            "volume": "29",
            "issn": "Suppl 4",
            "pages": "iv68-iv78",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up",
            "authors": [
                {
                    "first": "P.G.",
                    "middle": [],
                    "last": "Casali",
                    "suffix": ""
                },
                {
                    "first": "N.",
                    "middle": [],
                    "last": "Abecassis",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Bauer",
                    "suffix": ""
                },
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Biagini",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Bielack",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Ann Oncol",
            "volume": "29",
            "issn": "Suppl 4",
            "pages": "iv51-iv67",
            "other_ids": {
                "DOI": []
            }
        }
    }
}